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Abstract Two human mammary carcinoma cell variants,
MCF-7/AZ and MCF-7/6, show the same composition in their
glycosphingolipid-enriched microdomain (GEM) with regard to
globo-series structures Gb3, Gb4, Gb5, monosialyl-Gb5, GM2,
and cSrc and FAK. Both variants are non-invasive into collagen
gel layer, and showed similar motility in wound migration assay.
Whereas invasiveness and motility of MCF-7/AZ cells were
enhanced greatly by treatment with mAb RM1 directed to
monosialyl-Gb5, the same RM1 treatment had no e¡ect on
MCF-7/6. cSrc and FAK of MCF-7/AZ, but not MCF-7/6,
were activated by RM1 treatment. Thus, malignancy of
MCF-7 is highly dependent on monosialyl-Gb5, and its activa-
tion of cSrc and FAK in GEM.
1 2002 Federation of European Biochemical Societies. Pub-
lished by Elsevier Science B.V. All rights reserved.
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1. Introduction
Glycosphingolipids (GSLs) in tumors have been identi¢ed
as tumor-associated antigens de¢ned by speci¢c monoclonal
antibodies [1]. Essentially all GSLs, either in tumor cells or
normal cells, are clustered and assembled with speci¢c mem-
brane proteins and signal transducers to form ‘GSL-enriched
microdomain’ (GEM) or ‘glycosignaling domain’ (GSD) [2].
An interesting possibility is that tumor cell malignancy may
be de¢ned by organization of tumor-associated GSL antigens
in GEM or GSD, since they are known to be involved in (i)
GSL-dependent tumor cell adhesion, and (ii) signal transduc-
tion induced by stimulation of GSLs. Examples have been
shown for GM3 in mouse melanoma B16 [3^6], and for dis-
ialyl-GalNAcLc4 de¢ned by mAb RM2, in renal cell carcino-
ma [7,8].
In this paper, we present data on functional role of mono-
sialyl-Gb5 (MSGb5) in GEM of human mammary carcinoma
variant cell lines MCF-7/AZ and MCF-7/6, which show di¡er-
ential invasiveness and motility in response to stimulation of
MSGb5 by its mAb RM1.
2. Materials and methods
2.1. Cell lines, antibodies, and GSLs
MCF-7/AZ and MCF-7/6 cells [9] are variants of the human mam-
mary carcinoma cell family MCF-7 [10]. They were cultured in Dul-
becco’s modi¢ed Eagle’s medium (DMEM) and Ham’s F12 (50/50)
(Cellgro, VA, USA) with penicillin (250 IU/ml), streptomycin (100 Wg/
ml), and 10% fetal bovine serum (Cellgro). 7/AZ di¡er from 7/6 cells
in that their morphology changes (¢ngerlike extensions), with in-
creased membrane ru¥ing and penetration into collagen gel, upon
treatment with ET-18-OMe (25 Wg/ml; 50 WM) [11].
Anti-GSL antibodies used in this study were: mouse IgM MBr1 to
globo-H, mouse IgM 1A4 (E10) to Gb3, mouse IgG3 DH2 to GM3,
mouse IgM MK1-8 to GM2, mouse IgM 9G7 to Gb4, mouse IgM
SSEA3 to Gb5 (see table 4 of ref. [12] for source and reference of each
antibody), mouse IgM RM1 to MSGb5 [13], and mouse IgM 5F3 to
disialyl-Gb5 [14]. Antibodies to cSrc, phosphorylated activated cSrc,
FAK, and phosphorylated activated FAK (see Section 2.6).
Total GSLs were separated from phospholipids and other lipids by
acetylation procedure [15], further puri¢ed by HPTLC using Iatro-
beads 6RS-8010 in isopropanol/hexane/water system [16], and identi-
¢ed with thin-layer chromatography (TLC) immunostaining by spe-
ci¢c mAbs as above. The procedure has been described in detail [8].
2.2. GSL composition in GEM and soluble fractions by TLC
immunostaining
GEM and other fractions were separated from postnuclear fraction
by sucrose gradient density centrifugation, and their content of GSLs,
cSrc, and FAK was determined as described previously [5,17,18]. GSL
components in GEM were identi¢ed by high-performance TLC
(HPTLC) with immunostaining as above, following elimination of
sucrose by dialysis or C18 column [18]. cSrc, FAK, and various other
membrane proteins (integrins K1, K2, K3, CD9, MUC1, MUC4,
E-cadherin, L-catenin) were further identi¢ed by sodium dodecyl sul-
fate^polyacrylamide gel electrophoresis (SDS-PAGE) with Western
blotting. Intensity of immunoblotted bands was quanti¢ed by densi-
tometry, using the Scion Image program (Scion Corp., Frederick,
MD, USA). TLC immunostaining was performed as described previ-
ously [8].
Glycoproteins and signal transducer proteins present in GEM or in
high-density soluble fraction were determined by 8% SDS^PAGE fol-
lowed by Western blotting on PVDF membrane (Immobilon-P, Milli-
0014-5793 / 02 / $22.00 N 2002 Federation of European Biochemical Societies. Published by Elsevier Science B.V. All rights reserved.
PII: S 0 0 1 4 - 5 7 9 3 ( 0 2 ) 0 3 4 8 4 - 1
*Corresponding author. Fax: (1)-206-726 1212.
E-mail address: hakomor@u.washington.edu (S. Hakomori).
1 Present address: Department of Chemistry, New Mexico Tech., 801
Leroy Place, Socorro, NM 87801, USA.
Abbreviations: GEM, glycosphingolipid-enriched microdomain;
GSD, glycosignaling domain; GSL, glycosphingolipid; HPTLC,
high-performance thin-layer chromatography; SDS^PAGE, sodium
dodecyl sulfate^polyacrylamide gel electrophoresis
FEBS 26650 16-10-02
FEBS 26650 FEBS Letters 531 (2002) 93^98
pore) with relevant antibodies vs. CD9, cSrc, p-cSrc, MUC1, MUC4,
E-cadherin, FAK, p-FAK, K1, K2, and K3 (for sources, see Fig. 2
legend), followed by chemiluminescence method with a substrate kit
(Super-Signal-CL-HRP, Pierce), as described previously [18].
2.3. Immuno£uorescence detection of CD9
Cells were suspended in trypsin/EDTA and stained by an indirect
immuno£uorescence technique. Cells were incubated at 4‡C for 1 h
with primary antibody against CD9, followed by washing with PBS
and incubation in the dark at 4‡C for 1 h with an FITC-labeled goat
anti-mouse secondary antibody. Then cells were washed, ¢xed with
2% paraformaldehyde in PBS at room temperature for 20 min, and
analyzed by £ow cytometry with a Beckman Coulter with Expo32
software.
2.4. Invasion through collagen type I gel
This was determined as described previously [19]. Brie£y, neutral-
ized type I collagen (0.09%) was incubated for 1 h at 37‡C to allow
geli¢cation. Single-cell suspensions in DMEM/Ham’s F12 were pre-
pared with trypsin/EDTA, mixed with or without antibodies (for di-
lution of antibodies and concentration of cSrc kinase inhibitor, see
Fig. 3, legend), placed on top of collagen gel, and cultured at 37‡C for
24 h. Numbers of cells penetrating into gel or remaining at the surface
were counted in 12 ¢elds of 0.157 mm2, using an inverted microscope
controlled by a computer program. The invasion index expresses the
percentage of penetrating (invading) cells divided by total number of
cells.
2.5. Wound migration assay
The 7/AZ and 7/6 cells were cultured in 24-well Corning tissue
culture plates. After 40 h at 37‡C, the cells were wounded, a line
was scratched with a plastic scriber, debris was removed by washing,
and culture medium was added with or without antibody against
MSGb5 (MR-1), cSrc kinase inhibitor Pp1, or the combination of
the two. The distance between the borders was measured (t0) along
the well, using a grid in a Nikon phase-contrast inverted microscope
Fig. 1. TLC patterns of GSLs from whole cell extract (panel A) or present in GEM (panel B) of MCF-7/AZ and MCF-7/6 cells. Panel A:
GSLs were extracted from cells of the same protein weight, spotted onto HPTLC plates, developed in a solvent system of chloroform/metha-
nol/0.2% aqueous CaCl2 (50:40:10), visualized by spraying with 0.5% orcinol in 2 N sulfuric acid or immunostaining of MSGb5 (RM1), Gb5
(SSEA3) and GM2 (MK1-8), and separated on TLC. Panel B: Immunostaining of various GSL structures present in GEM (Fr. 4^6) and Fr.
11^13 by nine antibodies directed to the respective structures. GSL fraction was prepared after elimination of sucrose by dialysis.
C
Fig. 2. Panel A: Detection of glycoproteins and signal transducers in GEM (Fr. 4^6) and Fr. 11^13 from 7/AZ and 7/6 cells by SDS^PAGE
followed by Western blotting with respective antibodies as indicated at left. Glycoprotein carrying MBr1 epitope (Gp-MBR-1) was blotted by
MBr1 [29]. Mouse IgG 21404 to MUC1 was donated by Dr. John Hilkens (Dutch Cancer Institute, Amsterdam, The Netherlands). Rabbit
polyclonal antibodies to MUC4 were donated by Dr. Carme de Bolos (Institut Municipal d’Investigacio Medica, Barcelona, Spain). mAb
HECD-1 (mouse IgG) directed to E-cadherin was purchased from Takara Bio Inc. (Otsu, Shiga, Japan). Mouse IgG mAb to L-catenin was
from Sigma. Mouse IgG mAb to CD9 was from Becton-Dickinson (Lincoln Park, NJ, USA). mAbs directed to K1, K2, and K3 integrin recep-
tors were from Chemicon (Temecula, CA, USA). Panel B. Left: CD9 expression in 7/AZ (A) and 7/6 cells (B) determined by £ow cytometry.
CD9 £uorescence index was 60.0 for 7/AZ and 27.3 for 7/6 cells. Right: CD9 expression in GEM fraction of 7/AZ (white column) and 7/6
(black column), quanti¢ed by Scion image program.
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(Model 95023) with 40U magni¢cation. Experiments were done in
triplicate and the distance was measured in ¢ve ¢elds of each well.
After 8 h incubation at 37‡C, the distance between the borders in each
¢eld was measured again (tfinal). Migration was calculated as the dis-
tance moved by the advancing cells of both borders, divided by 2,
times migration hours, and expressed as Wm/h [20].
2.6. Levels of cSrc and FAK, and their activation state through tyrosine
phosphorylation
Cells stimulated for 0 min, 10 min, 30 min, or 48 h with antibody
against MSGb5 (RM1) were lysed in 0.5 ml lysis bu¡er (50 mM Tris/
HCl, pH 7.4, 150 mM NaCl, 1 mM EDTA, 75 U/ml aprotinin, 1%
Triton X-100). Aliquots of lysate containing the same quantity of
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protein (V100 Wg) were boiled for 5 min in SDS^PAGE sample bu¡-
er containing 5% 2-mercaptoethanol, electrophoresed on 8% SDS^
PAGE, transferred to PVDF membranes, and Western blotted.
To determine levels of cSrc and FAK and their activation state,
they were isolated from cell lysate by immunoprecipitation, followed
by Western blotting with speci¢c antibodies de¢ning tyrosine phos-
phate for cSrc and FAK. Brie£y, 400 Wl cell lysate (containing 40 Wg
protein) was mixed with 10 Wl protein G-Sepharose beads (Amersham
Pharmacia, Sweden) and rotated for 2 h at 4‡C. After centrifugation
(900Ug for 5 min), the supernatant was added with 2 Wl of 100 Wg/ml
mouse anti-FAK mAb (Transduction Laboratories) or 2 Wl of rabbit
anti-Src SRC2 (Santa Cruz Biotech, CA, USA), rotated overnight at
4‡C, and then incubated with 10 Wl protein G-Sepharose beads for 2 h
at 4‡C. After centrifugation at 900Ug for 5 min and washing of beads
with TBS, 0.05% Tween 20, samples were prepared for SDS^PAGE
followed by Western blotting with antibodies de¢ning PY416 (Cell
Signaling, Beverly, MA, USA) for cSrc, and PY397 (Bioscience Int.,
Camarillo, CA, USA) for FAK. The membranes were probed with
either horseradish peroxidase-conjugated goat anti-rabbit or anti-
mouse IgG, and developed as described above.
3. Results
3.1. Composition of GSLs in MCF-7/6 and MCF-7/AZ cells, in
GEM and in soluble fraction (Fr.) 11^13
Major GSLs found in these two MCF-7 variants were iden-
ti¢ed as globo-series Gb3, Gb4, Gb5, and K1C2 fucosyl-Gb5
(globo-H), de¢ned by TLC immunostaining with mAbs 1A4,
9G7 [21], MC631, and MBr1, respectively. A major slow-mi-
grating ganglioside was identi¢ed as MSGb5, de¢ned by mAb
RM1 (Fig. 1A). Ganglio-series structures (each de¢ned by
speci¢c mAb; see Section 2) such as GM3 and GM1 were
absent, but GM2 was present as a major component, over-
lapping with Gb5 (Fig. 1A). Lacto-series GSLs were not de-
tectable. Compositions of GSLs as above were compared for
Fr. 5 (GEM) vs. soluble high-density Fr. 11^13. Each GSL
was present in Fr. 5 but completely absent in Fr. 11^13 (Fig.
1B).
Presence of Gb3, and other globo-series structures similar
to Gb5 and fucosyl-Gb5, in MCF-7 cells was reported previ-
ously [22]. This previous paper also reported the abundant
presence of GM3 and GM1 in MCF-7 cells, but the variant
used in the present study lacked GM3 and GM1.
3.2. Other components found in GEM
Various membrane proteins and glycoproteins associated
with GEM (low-density Fr. 4^6) or associated with soluble
high-density Fr. 11^13 are shown in Fig. 2A,B. Levels of
integrins K1, K2, K3, and cSrc were essentially the same be-
tween 7/6 and 7/AZ. CD9 in 7/AZ was present at high level in
GEM, whereas CD9 in 7/6 was virtually absent in GEM. All
other membrane-associated proteins, i.e. MUC1, E-cadherin,
L-catenin, cSrc, and CD9, were found in GEM as well as in
Fr. 11^13. Levels of MUC1, E-cadherin, and L-catenin were
essentially identical between 7/6 and 7/AZ. All these compo-
nents in GEM of various types of cells are known to be in-
volved in cell adhesion coupled with signal transduction.
Because CD9 showed a major di¡erence between 7/6 and 7/
AZ, we compared cell surface expression patterns by £ow
cytometry. 7/AZ showed much higher expression than 7/6;
expression index was 60.0 vs. 27.3 (Fig. 2C). However, this
was much less than the di¡erence observed in CD9 level in
GEM, which was very low in 7/6 but high in 7/AZ (Fig. 2B,
left lower panel).
3.3. Anti-MSGb5 mAb RM1 strongly enhances motility and
invasiveness of 7/AZ but not 7/6 cells
Both 7/AZ and 7/6 cells are non-invasive through type I
collagen gel layer as determined by a method using a speci¢c
assembly [19], and motility of the two variants as determined
by wound migration assay is essentially the same. However,
when 7/AZ cells were treated with anti-MSGb5 mAb RM1,
their invasiveness and motility were greatly enhanced (Fig.
3A, columns ‘RM1’). Control IgG or IgM antibodies from
normal mouse serum, and antibodies to other GSLs (anti-
Gb3 1A4, anti-Gb5 SSEA-3, anti-GM2 MK1-8), did not en-
hance invasiveness or motility of either variant (Fig. 3A, all
other columns). When 7/AZ cells were pretreated with cSrc
kinase inhibitor Pp1, the enhancement of invasiveness and
motility as above was blocked (Fig. 3A, columns ‘Pp1’ and
‘RM1+Pp1’). 7/AZ cell motility determined by wound migra-
tion assay, indicating enhancement in the presence of RM1,
and its inhibition in the presence of Pp1, are shown in Fig. 3B
(top). 7/6 cell motility was not a¡ected by RM1 or Pp1 (Fig.
3B, bottom). Quantitative evaluation of 7/AZ cell motility
change in wound migration assay is shown in Fig. 3C.
3.4. RM1-dependent enhancement of cSrc and FAK activation
in 7/AZ cells, and absence of such e¡ect in 7/6 cells
The motility/invasion-promoting e¡ect of RM1 on 7/AZ
cells as above suggests that RM1 initiates signaling in 7/AZ
but not in 7/6 cells. We therefore examined e¡ect of RM1 on
activity of cSrc kinase and FAK. Chemical levels of cSrc and
FAK in both variants were unchanged by RM1 treatment,
but cSrc kinase activity and FAK activity in 7/AZ were
greatly increased after 10^30 min RM1 treatment (Fig. 4,
left panel). There was no such activation of cSrc or FAK
by RM1 treatment in 7/6 cells (Fig. 4, right panel).
4. Discussion
Metastatic and invasive properties of tumor cells are of
central importance for understanding tumor malignancy.
Any mechanism revealed could be a target for inhibition or
prevention of tumor progression. Many recent studies have
revealed that tumor cell penetration into extracellular matrix
(ECM), based on ECM-dependent enhanced motility coupled
with ECM-destructive activity, is often associated with high
metastasis (e.g. [23^25]). The present study is focused on:
(i) composition of GSLs, signal transducers, and other mem-
brane receptors in GEM fraction of two variants of breast
carcinoma cell line MCF-7, 7/AZ vs. 7/6; (ii) stimulation of
major ganglioside MSGb5 by its antibody RM1 enhances
motility and invasiveness through activation of cSrc and
FAK in 7/AZ but not 7/6 cells. These results suggest a close
connection of MSGb5 with cSrc and FAK in GEM, although
co-immunoprecipitation was di⁄cult to perform since RM1 is
IgM. In contrast, GM3 was successfully co-immunoprecipi-
tated with cSrc, RhoA, and FAK in B16 melanoma cells in
our previous studies [5,6], since anti-GM3 antibody is IgG3.
Nevertheless, it is plausible that MSGb5 in GEM, stimulated
by RM1, may initiate a signal leading to strong enhancement
of tumor cell penetration into collagen gel, and of cell motility
as determined by wound migration assay. This connection was
observed only in 7/AZ, but not in 7/6. The connection was
evidenced by tyrosine kinase activation of cSrc and FAK
following stimulation of MSGb5 by its mAb RM1 in 7/AZ,
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Fig. 3. Panel A: E¡ect of mouse IgM or antibodies against Gb3 (1A4), Gb5 (SSEA3), globo-H (MBr1), MSGb5 (RM1), GM2 (MK1-8), cSrc
kinase inhibitor (Pp1), or RM1 plus Pp1, on invasion into collagen type I of 7/AZ (white columns) and 7/6 cells (black columns). Bars indicate
standard deviation; asterisks indicate statistical di¡erence from controls (7/AZ and 7/6 without antibodies). 1:10 dilution was used for 1A4,
SSEA3, and RM1 since they are hybridoma culture supernatants; 1:1000 dilution was used for MBr1 and MK1-8 since they are ascites or pu-
ri¢ed samples; 1:100 dilution was used for control puri¢ed IgM. At these dilutions, approximate mouse IgM concentration was 1.5^3.0 Wg/ml.
Final concentration of Pp1 was 20 WM. Panel B: E¡ect of anti-MSGb5 antibody (RM1; dilution 1:10) or cSrc kinase inhibitor (Pp1; 20 WM)
on 7/AZ and 7/6 migration in wound migration assay. Cells were plated in 24-well plates. After 40 h, cells were wounded, and allowed migra-
tion for 8 h in the presence of RM1, Pp1, or both. Scale bar= 250 Wm. Panel C: Migration (expressed in Wm/h) of 7/AZ and 7/6 cells in wound
migration assay (see text). Open bars, controls (mouse IgM). Black bars, cultured in presence of RM1 (dilution 1:10). Striped bars, cultured in
presence of RM1 plus Pp1 (20 WM).
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and lack of such response in 7/6. A search for any di¡erential
level of GSLs, transducers, or membrane receptors (MUC1,
MUC4, E-cadherin, integrins K1, K2, K3) in 7/AZ vs. 7/6 was
unsuccessful. The only di¡erence between the two variants
was in CD9 level, which cannot be logically correlated with
RM1-induced cSrc or FAK activation, nor with induction of
invasiveness/motility. Since CD9 level was high in GEM frac-
tion of 7/AZ but essentially zero in GEM of 7/6, there is a
possibility that CD9 in 7/AZ GEM may mediate connection
of stimuli caused by RM1-induced clustering of MSGb5 with
activation of cSrc and FAK. However, co-immunoprecipita-
tion was not observed between CD9 and cSrc or FAK under
conditions used in this study. The connection may be medi-
ated by a yet-unexplored lipid such as cholesterol or sphingo-
myelin, which are enriched in GEM fraction, as is CD9. This
idea is plausible in view of the recent identi¢cation of CD9 as
a proteolipid, a highly lipophilic component.
MSGb5 and FucGb5 (globo-H) are tumor-associated anti-
gens. The current results suggest that stimulation of MSGb5
through its antibody RM1 activates cell motility and invasive-
ness, although the pathobiological implications of this phe-
nomenon remain to be studied. It is plausible that MCF-7
cell adhesion to target cells is mediated by binding receptor
(e.g. siglec) or complementary carbohydrate (through carbo-
hydrate-to-carbohydrate interaction), and that this step is fol-
lowed by transducer activation leading to enhanced invasive-
ness of MCF-7 cells. Such process, in general, is consistent
with our predictions for ‘‘Type 1 glycosynapse’’ [26], and is
analogous to melanoma cell binding to endothelial cells
through melanoma-associated GM3 antigen followed by
transducer activation [4,27,28].
An alternative possibility is that MSGb5 in both 7/AZ and
7/6 cells has an inherent inhibitory e¡ect on cell motility,
through inhibition of cSrc and FAK. RM1 may block such
inhibitory e¡ect, and the extent of such blocking may di¡er
between 7/AZ and 7/6 cells because of their di¡erent CD9
level.
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Fig. 4. Time course e¡ect of anti-MSGb5 mAb RM1 on activity of
cSrc and FAK kinases in 7/AZ vs. 7/6 cells, determined by blotting
with antibodies de¢ning PY416 for cSrc, and PY397 for FAK.
Quantity of cSrc was determined using antibody SRC2. Notations
at left margin: cSrc, quantity of cSrc; p-cSrc, level of PY416;
FAK, quantity of FAK; p-FAK, level of PY397, at times indicated
at top. Notations at right margin: molecular mass (kDa).
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